Precision BioSciences Announces Change to its Board of Directors
11 November 2022 - 9:00AM
Business Wire
- Raymond F. Schinazi, Ph.D., to Step Down from
Board of Directors and Continue as a Member of the Company’s
Scientific Advisory Board (SAB)
Precision BioSciences, Inc. (Nasdaq: DTIL), a clinical stage
gene editing company developing ARCUS®-based ex vivo allogeneic CAR
T and in vivo gene editing therapies, today announced that Dr.
Raymond Schinazi is stepping down from the company’s Board of
Directors and will continue as a member of the company’s SAB,
lending his deep expertise in antiviral drug discovery and
development.
“Ray is a trusted advisor, and since early 2019 when he joined
the Board, has provided Precision with incredible perspective and
support for the company’s CAR T and in vivo gene editing pipeline,
particularly the development of ARCUS nucleases as an in vivo gene
editing strategy to deliver a potential functional cure for chronic
hepatitis B,” said Kevin Buehler, Chairman of the Board. “While we
will miss having Ray on the Board, we look forward to continuing
working with him as a SAB member. This change provides the
opportunity for us to continue refreshing our Board with new
independent directors that bring additional diverse experience and
relevant expertise to Precision.”
“I’d like to thank Precision for the opportunity to work with an
incredible team and a gene editing industry leader focused on
developing potentially transformative treatment and curative
options for high unmet needs,” said Dr. Schinazi. “I am confident
the company will have continued success and I look forward to
focusing my efforts on Precision’s SAB to further contribute to the
development of its innovative in vivo pipeline, including a new,
much-needed and potentially curative modality for chronic hepatitis
B.”
Dr. Schinazi’s resignation from the Board of Directors was
effective as of November 5, 2022.
About Precision BioSciences, Inc.
Precision BioSciences, Inc. is a clinical stage biotechnology
company dedicated to improving life (DTIL) with its novel and
proprietary ARCUS® genome editing platform. ARCUS is a highly
precise and versatile genome editing platform that was designed
with therapeutic safety, delivery, and control in mind. Using
ARCUS, the company’s pipeline consists of multiple ex vivo
“off-the-shelf” CAR T immunotherapy clinical candidates and several
in vivo gene editing candidates designed to cure genetic and
infectious diseases where no adequate treatments exist. For more
information about Precision BioSciences, please visit
www.precisionbiosciences.com.
Forward-Looking Statements
This press release contains forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995. All statements contained in this press release that do not
relate to matters of historical fact should be considered
forward-looking statements, including, without limitation,
statements regarding the development and potential efficacy of
Precision’s product candidates and potential functional cure for
chronic hepatitis B. In some cases, you can identify
forward-looking statements by terms such as “aim,” “anticipate,”
“approach,” “believe,” “contemplate,” “could,” “estimate,”
“expect,” “goal,” “intend,” “look,” “may,” “mission,” “plan,”
“possible,” “potential,” “predict,” “project,” “should,” “target,”
“will,” “would,” or the negative thereof and similar words and
expressions.
Forward-looking statements are based on management’s current
expectations, beliefs and assumptions and on information currently
available to Precision. Such statements are subject to a number of
known and unknown risks, uncertainties and assumptions, and actual
results may differ materially from those expressed or implied in
the forward-looking statements due to various important factors,
including, but not limited to: Precision’s ability to become
profitable; Precision’s ability to procure sufficient funding and
requirements under its current debt instruments and effects of
restrictions thereunder; risks associated with raising additional
capital; Precision’s operating expenses and its ability to predict
what those expenses will be; Precision’s limited operating history;
the success of its programs and product candidates in which it
expends its resources; Precision’s limited ability or inability to
assess the safety and efficacy of its product candidates;
Precision’s dependence on its ARCUS technology; the initiation,
cost, timing, progress, achievement of milestones and results of
research and development activities, preclinical studies and
clinical trials; public perception about genome editing technology
and its applications; competition in the genome editing,
biopharmaceutical, and biotechnology fields; Precision’s or its
collaborators’ ability to identify, develop and commercialize
product candidates; and other important factors discussed under the
caption “Risk Factors” in Precision’s Quarterly Report on Form 10-Q
for the quarterly period ended September 30, 2022, filed with the
SEC, as any such factors may be updated from time to time in our
other filings with the SEC, which are accessible on the SEC’s
website at www.sec.gov and the Investors page of Precision’s
website under SEC Filings at investor.precisionbiosciences.com.
All forward-looking statements speak only as of the date of this
press release and, except as required by applicable law, Precision
has no obligation to update or revise any forward-looking
statements contained herein, whether as a result of any new
information, future events, changed circumstances or otherwise.
View source
version on businesswire.com: https://www.businesswire.com/news/home/20221110006055/en/
Investor Contact: Mei Burris Director, Investor Relations
and Finance Mei.Burris@precisionbiosciences.com Media
Contact: Maurissa Messier Senior Director, Corporate
Communications Maurissa.Messier@precisionbiosciences.com
Precision BioSciences (NASDAQ:DTIL)
Historical Stock Chart
From Apr 2024 to May 2024
Precision BioSciences (NASDAQ:DTIL)
Historical Stock Chart
From May 2023 to May 2024